Brigatinib: A Review in ALK-Inhibitor Naïve Advanced ALK-Positive NSCLC.

Abstract

Brigatinib (Alunbrig®) is an oral, potent and selective anaplastic lymphoma kinase (ALK) and c-ros oncogene 1 (ROS1) tyrosine kinase inhibitor approved for treating adults with advanced ALK-positive non-small-cell lung cancer (NSCLC) not previously treated with an ALK inhibitor. In a multinational, phase III study (ALTA-1L) in this patient population, brigatinib significantly improved median blinded independent review committee-assessed progression-free survival (PFS), the confirmed objective response (OR) rate and the confirmed intracranial OR rate compared with crizotinib. Its tolerability profile in this study was manageable and no new safety concerns were identified. Although final analysis data are awaited with interest, brigatinib therapy extends the first-line treatment options available for standard of care in this patient population, including patients with CNS metastases.

• Authors: Sheridan M Hoy
• Journal: Drugs (Drugs) Vol. 81 Issue 2 Pg. 267-275 (Feb 2021) ISSN: 1179-1950 [Electronic] New Zealand
• PMID: 33528789 (Publication Type: Journal Article, Review)

Chemical References

• Antineoplastic Agents
• Organophosphorus Compounds
• Protein Kinase Inhibitors
• Pyrimidines
• ALK protein, human
• Anaplastic Lymphoma Kinase
• brigatinib

Topics

• Administration, Oral
• Anaplastic Lymphoma Kinase (antagonists & inhibitors, metabolism)
• Antineoplastic Agents (administration & dosage, pharmacology)
• Carcinoma, Non-Small-Cell Lung (drug therapy, metabolism)
• Humans
• Lung Neoplasms (drug therapy, metabolism)
• Organophosphorus Compounds (administration & dosage, pharmacology)
• Protein Kinase Inhibitors (administration & dosage, pharmacology)
• Pyrimidines (administration & dosage, pharmacology)